```
  Query Match             100.0%;  Score 1831;  DB 17;  Length 352;
  Best Local Similarity   100.0%;  Pred. No. 1.6e-162;
  Matches  352;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MESGGRPSLCQFILLGTTSVVTAALYSVYRQKARVSQELKGAKKVHLGEDLKSILSEAPG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MESGGRPSLCQFILLGTTSVVTAALYSVYRQKARVSQELKGAKKVHLGEDLKSILSEAPG 60

Qy         61 KCVPYAVIEGAVRSVKETLNSQFVENCKGVIQRLTLQEHKMVWNRTTHLWNDCSKIIHQR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KCVPYAVIEGAVRSVKETLNSQFVENCKGVIQRLTLQEHKMVWNRTTHLWNDCSKIIHQR 120

Qy        121 TNTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLETVYEKFHPSIQSFTDVIGHYISGERPK 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 TNTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLETVYEKFHPSIQSFTDVIGHYISGERPK 180

Qy        181 GIQETEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYYLSSQDFDSLLQRQESSVRLW 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 GIQETEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYYLSSQDFDSLLQRQESSVRLW 240

Qy        241 KVLALVFGFATCATLFFILRKQYLQRQERLRLKQMQEEFQEHEAQLLSRAKPEDRESLKS 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 KVLALVFGFATCATLFFILRKQYLQRQERLRLKQMQEEFQEHEAQLLSRAKPEDRESLKS 300

Qy        301 ACVVCLSSFKSCVFLECGHVCSCTECYRALPEPKKCPICRQAITRVIPLYNS 352
              ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 ACVVCLSSFKSCVFLECGHVCSCTECYRALPEPKKCPICRQAITRVIPLYNS 352


RESULT 9
US-09-764-864-801
; Sequence 801, Application US/09764864
; Patent No. US20020132753A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
;  FILE REFERENCE: PTZ23
;  CURRENT APPLICATION NUMBER: US/09/764,864
;  CURRENT FILING DATE:  2001-01-17
;  Prior application data removed - consult PALM or file wrapper
;  NUMBER OF SEQ ID NOS: 1792
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 801
;   LENGTH: 392
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: SITE
;   LOCATION: (238)
;   OTHER INFORMATION: Xaa equals any of the naturally occurring L-amino acids
US-09-764-864-801

  Query Match             99.7%;  Score 1826;  DB 9;  Length 392;
  Best Local Similarity   99.7%;  Pred. No. 5.5e-162;
  Matches  351;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MESGGRPSLCQFILLGTTSVVTAALYSVYRQKARVSQELKGAKKVHLGEDLKSILSEAPG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         41 MESGGRPSLCQFILLGTTSVVTAALYSVYRQKARVSQELKGAKKVHLGEDLKSILSEAPG 100

Qy         61 KCVPYAVIEGAVRSVKETLNSQFVENCKGVIQRLTLQEHKMVWNRTTHLWNDCSKIIHQR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        101 KCVPYAVIEGAVRSVKETLNSQFVENCKGVIQRLTLQEHKMVWNRTTHLWNDCSKIIHQR 160

Qy        121 TNTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLETVYEKFHPSIQSFTDVIGHYISGERPK 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        161 TNTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLETVYEKFHPSIQSFTDVIGHYISGERPK 220

Qy        181 GIQETEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYYLSSQDFDSLLQRQESSVRLW 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        221 GIQETEEMLKVGATLTGXGELVLDNNSVRLQPPKQGMQYYLSSQDFDSLLQRQESSVRLW 280

Qy        241 KVLALVFGFATCATLFFILRKQYLQRQERLRLKQMQEEFQEHEAQLLSRAKPEDRESLKS 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        281 KVLALVFGFATCATLFFILRKQYLQRQERLRLKQMQEEFQEHEAQLLSRAKPEDRESLKS 340

Qy        301 ACVVCLSSFKSCVFLECGHVCSCTECYRALPEPKKCPICRQAITRVIPLYNS 352
              ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        341 ACVVCLSSFKSCVFLECGHVCSCTECYRALPEPKKCPICRQAITRVIPLYNS 392


RESULT 10
US-10-024-298A-73
; Sequence 73, Application US/10024298A
; Publication No. US20030143540A1
; GENERAL INFORMATION:
;  APPLICANT: ASAHI KASEI KABUSHIKI KAISHA
;  APPLICANT:  Akio MATSUDA
;  APPLICANT:  Goichi HONDA
;  APPLICANT:  Shuji MURAMATSU
;  APPLICANT:  Yukiko NAGANO
;  TITLE OF INVENTION: NF-K B Activating Gene
;  FILE REFERENCE: 1254-0191P
;  CURRENT APPLICATION NUMBER: US/10/024,298A
;  CURRENT FILING DATE:  2003-04-08
;  PRIOR APPLICATION NUMBER: 60/314,385
;  PRIOR FILING DATE: 2001-08-24
;  PRIOR APPLICATION NUMBER: 60/278,641
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: 60/258,315
;  PRIOR FILING DATE: 2000-12-28
;  PRIOR APPLICATION NUMBER: JP254018/2001
;  PRIOR FILING DATE: 2001-08-24
;  PRIOR APPLICATION NUMBER: JP0088912/2001
;  PRIOR FILING DATE: 2001-03-26
;  PRIOR APPLICATION NUMBER: JP402288/2000
;  PRIOR FILING DATE: 2000-12-28
;  NUMBER OF SEQ ID NOS: 182
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 73
;   LENGTH: 352
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-024-298A-73

  Query Match             99.6%;  Score 1824;  DB 14;  Length 352;
  Best Local Similarity   99.7%;  Pred. No. 7.3e-162;
  Matches  351;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MESGGRPSLCQFILLGTTSVVTAALYSVYRQKARVSQELKGAKKVHLGEDLKSILSEAPG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MESGGRPSLCQFILLGTTSVVTAALYSVYRQKARVSQELKGAKKVHLGEDLKSILSEAPG 60

Qy         61 KCVPYAVIEGAVRSVKETLNSQFVENCKGVIQRLTLQEHKMVWNRTTHLWNDCSKIIHQR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KCVPYAVIEGAVRSVKETLNSQFVENCKGVIQRLTLQEHKMVWNRTTHLWNDCSKIIHQR 120

Qy        121 TNTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLETVYEKFHPSIQSFTDVIGHYISGERPK 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 TNTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLETVYEKFHPSIQSFTDVIGHYISGERPK 180

Qy        181 GIQETEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYYLSSQDFDSLLQRQESSVRLW 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 GIQETEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYYLSSQDFDSLLQRQESSVRLW 240

Qy        241 KVLALVFGFATCATLFFILRKQYLQRQERLRLKQMQEEFQEHEAQLLSRAKPEDRESLKS 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 KVLALVFGFATCATLFFILRKQYLQRQERLRLKQMQEEFQEHEAQLLSRAKPEDRESLKS 300

Qy        301 ACVVCLSSFKSCVFLECGHVCSCTECYRALPEPKKCPICRQAITRVIPLYNS 352
              |||||||||||||||||||||||||||||||||||||||||||||||||| |||
Db        301 ACVVCLSSFKSCVFLECGHVCSCTECYRALPEPKKCPICRQAITRVIPPYNS 352


RESULT 11
US-10-042-211A-73
```

CC storing the sequence data on a computer system, and a method for
CC identifying features of the cDNA sequences using a computer programme.
CC The cDNAs are useful for expressing secreted proteins or fragments to
CC obtain antibodies capable of specifically binding to the secreted
CC proteins. The cDNAs may also be useful in diagnostic, forensic, gene
CC therapy and chromosome mapping procedures and may be used to design
CC expression vectors and secretion vectors. The proteins of the invention
CC may be used to treat diseases including cancer, autoimmune diseases,
CC cardiovascular disorders, cystic fibrosis, hypothyroidism, immunological
CC disorders, amyloidosis, brain disorders, skeletal muscle disorders, eye
CC disorders, obesity, mitochondriocytopathies, diabetes, atherosclerosis,
CC neurodegenerative disorders, graft rejection, Alzheimer's disease,
CC dementia, hyperlipidaemia, septic shock and impotence
XX
SQ Sequence 352 AA;

Query Match 100.0%; Score 1831; DB 3; Length 352;
Best Local Similarity 100.0%; Pred. No. 1.2e-168;
Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MESGGRPSLCQFILLGTTSVVTAALYSVYRQKARVSQELKGAKKVHLGEDLKSILSEAPG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MESGGRPSLCQFILLGTTSVVTAALYSVYRQKARVSQELKGAKKVHLGEDLKSILSEAPG 60

Qy         61 KCVPYAVIEGAVRSVKETLNSQFVENCKGVIQRLTLQEHKMVWNRTTHLWNDCSKIIHQR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KCVPYAVIEGAVRSVKETLNSQFVENCKGVIQRLTLQEHKMVWNRTTHLWNDCSKIIHQR 120

Qy        121 TNTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLETVYEKFHPSIQSFTDVIGHYISGERPK 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 TNTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLETVYEKFHPSIQSFTDVIGHYISGERPK 180

Qy        181 GIQETEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYYLSSQDFDSLLQRQESSVRLW 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 GIQETEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYYLSSQDFDSLLQRQESSVRLW 240

Qy        241 KVLALVFGFATCATLFFILRKQYLQRQERLRLKQMQEEFQEHEAQLLSRAKPEDRESLKS 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 KVLALVFGFATCATLFFILRKQYLQRQERLRLKQMQEEFQEHEAQLLSRAKPEDRESLKS 300

Qy        301 ACVVCLSSFKSCVFLECGHVCSCTECYRALPEPKKCPICRQAITRVIPLYNS 352
              ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 ACVVCLSSFKSCVFLECGHVCSCTECYRALPEPKKCPICRQAITRVIPLYNS 352
```

RESULT 2
AAE06602
ID AAE06602 standard; protein; 352 AA.
XX
AC AAE06602;
XX
DT 25-SEP-2001 (first entry)
XX
DE Human protein having hydrophobic domain, HP10649.
XX
KW Human; hydrophobic domain; gene therapy; nutritional supplement;
KW cell proliferation; immunomodulatory; autoimmune disorder; antimicrobial;
KW multiple sclerosis; rheumatoid arthritis; insulin-dependent diabetes;
KW haematopoiesis; tissue growth activity; Parkinson's disease; cytostatic;
KW Huntington's disease; Alzheimer's disease; chemotactic; chemokinetic;
KW haemostatic; thrombolytic; tumour growth inhibitor; anabolic;
KW contraceptive; antiinfertility; antiinflammatory.
XX
OS Homo sapiens.
XX
PN WO200149728-A2.
XX
PD 12-JUL-2001.
XX
PF 28-DEC-2000; 2000WO-JP009359.
XX
PR 06-JAN-2000; 2000JP-00000585.
PR 06-JAN-2000; 2000JP-00000588.
PR 11-JAN-2000; 2000JP-00002299.
PR 03-FEB-2000; 2000JP-00026862.
PR 03-MAR-2000; 2000JP-00058367.
XX
PA (PROT-) PROTEGENE INC.
PA (SAGA) SAGAMI CHEM RES CENT.
XX
PI Kato S, Kimura T;
XX
DR WPI; 2001-418355/44.
DR N-PSDB; AAD12597.
XX
PT Human proteins with hydrophobic domains and the nucleic acids encoding
PT them, useful for preventing diagnosing and treating e.g. cancer,
PT Alzheimer's and inflammation.
XX
PS Claim 1; Page 122; 563pp; English.
XX
CC The present sequence is human protein with hydrophobic domain, HP10649.
CC The polynucleotide and polypeptide of the invention may be used in the
CC prevention, diagnosis and treatment of diseases associated with
CC inappropriate polypeptide expression. The polynucleotides may be used to
CC produce the polypeptide, by inserting the nucleic acids into a host cell
CC and culturing the cell to express the protein. The polynucleotides and
CC its complementary sequences may also be used as DNA probes in diagnostic
CC assays and also used in gene therapy. The polypeptides may also be used
CC as antigens in the production of antibodies and in assays to identify
CC modulators of polypeptide expression and activity. The polypeptides and
CC nucleic acids may be used as nutritional supplements, to modulate
CC cytokine and cell proliferation activity, to modulate immune stimulation
CC or suppression (e.g. for the treatment of microbial infections and
CC autoimmune disorders such as multiple sclerosis, rheumatoid arthritis and
CC insulin-dependent diabetes), to modulate haematopoiesis, to modulate
CC tissue growth activity (e.g. for the treatment of Parkinson's disease,
CC Huntington's disease and Alzheimer's disease), to modulate activin and
CC inhibin activity (e.g. for controlling fertility), to modulate
CC chemotactic and chemokinetic activity, to modulate haemostatic and
CC thrombolytic activity, to modulate receptor ligand activity, to modulate
CC inflammation and to inhibit tumour growth
XX
SQ Sequence 352 AA;

Query Match 100.0%; Score 1831; DB 4; Length 352;
Best Local Similarity 100.0%; Pred. No. 1.2e-168;
Matches 352; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MESGGRPSLCQFILLGTTSVVTAALYSVYRQKARVSQELKGAKKVHLGEDLKSILSEAPG 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MESGGRPSLCQFILLGTTSVVTAALYSVYRQKARVSQELKGAKKVHLGEDLKSILSEAPG 60

Qy         61 KCVPYAVIEGAVRSVKETLNSQFVENCKGVIQRLTLQEHKMVWNRTTHLWNDCSKIIHQR 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 KCVPYAVIEGAVRSVKETLNSQFVENCKGVIQRLTLQEHKMVWNRTTHLWNDCSKIIHQR 120

Qy        121 TNTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLETVYEKFHPSIQSFTDVIGHYISGERPK 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 TNTVPFDLVPHEDGVDVAVRVLKPLDSVDLGLETVYEKFHPSIQSFTDVIGHYISGERPK 180

Qy        181 GIQETEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYYLSSQDFDSLLQRQESSVRLW 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 GIQETEEMLKVGATLTGVGELVLDNNSVRLQPPKQGMQYYLSSQDFDSLLQRQESSVRLW 240

Qy        241 KVLALVFGFATCATLFFILRKQYLQRQERLRLKQMQEEFQEHEAQLLSRAKPEDRESLKS 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 KVLALVFGFATCATLFFILRKQYLQRQERLRLKQMQEEFQEHEAQLLSRAKPEDRESLKS 300

Qy        301 ACVVCLSSFKSCVFLECGHVCSCTECYRALPEPKKCPICRQAITRVIPLYNS 352
              ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 ACVVCLSSFKSCVFLECGHVCSCTECYRALPEPKKCPICRQAITRVIPLYNS 352
```

RESULT 3
ABB50174